Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

555558 Rho/SRF Pathway Inhibitor, CCG-1423 - CAS 285986-88-1 - Calbiochem

555558
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
285986-88-1C₁₈H₁₃ClF₆N₂O₃

Products

Catalogue NumberPackaging Qty/Pack
555558-25MG Sklená flaša 25 mg
Description
OverviewA cell-permeable benzamide compound that acts as an effective inhibitor against RhoA- and RhoC-mediated cellular activities by targeting signaling events downstream of Gα12/13 and RhoA/C, affecting MKL recruitment and/or postrecruitment function of MKL1, but not SRF-SRE interaction or ROCK kinase activity. CCG-1423 is shown to inhibit RhoC-dependent cell growth in A375M2 and SK-Mel-147 (IC50 ≤300 nM) and block RhoC/ Gα12-mediated PC-13 invasion in Matrigel assays (by ~90% at 3 µM). Shown to inhibit MICAL-2 with a Ki of 1.5 µM.
Catalogue Number555558
Brand Family Calbiochem®
SynonymsN-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide, MICAL-2 Inhibitor I, MRTF-A/SRF Transcription Inhibitor I, MLK1/SRF Transcription Inhibitor I
References
ReferencesLundquist, M.R., et al. 2014. Cell 156, 563..
Evelyn, C.R., et al. 2007. Mol. Cancer Ther. 6, 2249.
Product Information
CAS number285986-88-1
FormWhite solid
Hill FormulaC₁₈H₁₃ClF₆N₂O₃
Chemical formulaC₁₈H₁₃ClF₆N₂O₃
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥95% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
555558-25MG 04055977268478

Documentation

Rho/SRF Pathway Inhibitor, CCG-1423 - CAS 285986-88-1 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

Rho/SRF Pathway Inhibitor, CCG-1423 - CAS 285986-88-1 - Calbiochem Certificates of Analysis

TitleLot Number
555558

References

Reference overview
Lundquist, M.R., et al. 2014. Cell 156, 563..
Evelyn, C.R., et al. 2007. Mol. Cancer Ther. 6, 2249.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-January-2014 JSW
SynonymsN-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide, MICAL-2 Inhibitor I, MRTF-A/SRF Transcription Inhibitor I, MLK1/SRF Transcription Inhibitor I
DescriptionA cell-permeable benzamide compound that acts as an effective inhibitor against RhoA- and RhoC-mediated cellular activities by targeting signaling events downstream of Gα12/13 and RhoA/C, affecting MKL recruitment and/or postrecruitment function of MKL1, but not SRF-SRE interaction or ROCK kinase activity. CCG-1423 is shown to inhibit RhoC-dependent cell growth in A375M2 and SK-Mel-147 (IC50 ≤300 nM) and block RhoC/ Gα12-mediated PC-13 invasion in Matrigel assays (by ~90% at 3 µM). Shown to inhibit MICAL-2 with a Ki of 1.5 µM.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number285986-88-1
Chemical formulaC₁₈H₁₃ClF₆N₂O₃
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (10 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesLundquist, M.R., et al. 2014. Cell 156, 563..
Evelyn, C.R., et al. 2007. Mol. Cancer Ther. 6, 2249.